Trial Profile
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 09 Sep 2022 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 09 Sep 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.
- 31 Jan 2022 Planned End Date changed from 1 Aug 2021 to 1 Aug 2023.